Naziv |
Akcije |
(EMPA-REG OUTCOME Investigators) Verma, Subodh ; ...Tušek, Srećko ; Mirošević, Gorana, Goldoni, Vesna ; Jurišić-Eržen, Dubravka ; Balaško, Annemarie ; Balić, Stjepan ; Drvodelić- Šunić, Ema ; Canecki Varžić, Silvija ; ... Zinman, Bernard
Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes // Journal of the American College of Cardiology, 73 (2019), 21; 2780-2782. doi: 10.1016/j.jacc.2019.03.002 |
|
(EMPA-REG OUTCOME Investigators) Wanner, Christoph ; ... Tušek, Srećko ; Mirošević, Gorana ; Goldoni, Vesna ; Jurišić- Eržen, Dubravka ; Balaško, Annemarie ; Balić, Stjepan ; Drvodelić- Šunić, Ema ; Canecki Varžić, Silvija ; ..Groop, Per-Henrik
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial // Journal of the American Society of Nephrology, 29 (2018), 11; 2755-2769. doi: 10.1681/asn.2018010103 |
|
(EMPA-REG OUTCOME Investigators) Zinman, Bernard ; ... Tušek, Srećko ; Mirošević, Gorana ; Goldoni, Vesna ; Jurišić- Eržen, Dubravka ; Balaško, Annemarie ; Balić, Stjepan ; Drvodelić- Šunić, Ema ; Canecki Varžić, Silvija ; ... et al.
Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME® // Diabetologia (Berlin), 61 (2018), 7; 1522-1527. doi: 10.1007/s00125-018-4630-2 |
|
(EMPA-REG OUTCOME Investigators) Wanner, Christoph ; ... Tušek, Srećko ; Mirošević, Gorana, Goldoni, Vesna ; Jurišić-Eržen, Dubravka ; Balaško, Annemarie ; Balić, Stjepan ; Drvodelić- Šunić, Ema ; Canecki Varžić, Silvija ; ...Zinman, Bernard ;
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease // Circulation, 137 (2018), 2; 119-129. doi: 10.1161/circulationaha.117.028268 |
|
(EMPA-REG OUTCOME Investigators) Fitchett, David ; ...Tušek, Srećko ; Mirošević, Gorana, Goldoni, Vesna ; Jurišić-Eržen, Dubravka ; Balaško, Annemarie ; Balić, Stjepan ; Drvodelić- Šunić, Ema ; Canecki Varžić, Silvija ; ... ; Inzucchi, Silvio E ;
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial // European heart journal, 39 (2017), 5; 363-370. doi: 10.1093/eurheartj/ehx511 |
|
(EMPA-REG OUTCOME Investigators) Zinman, Bernard ; ... ; Tušek, Srećko ; Mirošević, Gorana, Goldoni, Vesna ; Jurišić-Eržen, Dubravka ; Balaško, Annemarie ; Balić, Stjepan ; Drvodelić- Šunić, Ema ; Canecki Varžić, Silvija ; ... et al.
Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk // Stroke, 48 (2017), 5; 1218-1225. doi: 10.1161/strokeaha.116.015756 |
|
(EMPA-REG OUTCOME Investigators) Kaku, Kohei ; ... Tušek, Srećko ; Mirošević, Gorana, Goldoni, Vesna ; Jurišić-Eržen, Dubravka ; Balaško, Annemarie ; Balić, Stjepan ; Drvodelić- Šunić, Ema ; Canecki Varžić, Silvija ; ...Woerle, Hans-Juergen
Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease ― Results From EMPA-REG OUTCOME<sup>®</sup> ― // Circulation journal, 81 (2017), 2; 227-234. doi: 10.1253/circj.cj-16-1148 |
|
(EMPA-REG OUTCOME Investigators) Wanner, Christoph ; ...Tušek, Srećko ; Mirošević, Gorana, Goldoni, Vesna ; Jurišić-Eržen, Dubravka ; Balaško, Annemarie ; Balić, Stjepan ; Drvodelić- Šunić, Ema ; Canecki Varžić, Silvija ; ...Zinman, Bernard
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes // The New England journal of medicine, 375 (2016), 4; 323-334. doi: 10.1056/nejmoa1515920 |
|
Rahelić, Dario ; Altabas, Velimir ; Bakula, Miro ; Balić, Stjepan ; Balint, Ines ; Bergman Marković, Biserka ; Bičanić, Nenad ; Bjelinski, Igor ; Božikov, Velimir ; Canecki Varžić, Silvija et al.
Hrvatske smjernice za farmakološko liječenje šećerne bolesti tipa 2 // Liječnički vjesnik : glasilo Hrvatskoga liječničkog zbora, 138 (2016), 1-2; 1-21 |
|
Liberati-Čizmek, A-M. ; Bakula, M. ; Balić, S.
Melatonin - novo lice moderne dijabetologije // Knjiga sažetaka 76. dani dijabetologa. 2015. str. --- |
|